 CAMBRIDGE, Mass., July 31, 2020 GLOBE NEWSWIRE -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on August 5, 2020, to discuss its second quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellations website at To participate in the live question-and-answer session, please dial 877 473-2077 domestic or 661 378-9662 international and refer to conference ID 4372778. About Constellation PharmaceuticalsConstellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates. ContactsKia Khaleghpour Vice President, Investor Relations and Communications Constellation Pharmaceuticals 1 617-844-6859 Aldridge Senior Director, Investor Relations Constellation Pharmaceuticals 1 617-714-0539 Arnold Media Relations MacDougall Biomedical Communications 1 781-235-3060 